Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.550
+0.001 (0.09%)
Inactive · Last trade price on Feb 11, 2025

Marinus Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Feb '25 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
30593197437434178
Upgrade
Market Cap Growth
-77.83%200.39%-54.79%0.58%144.36%17.88%
Upgrade
Enterprise Value
83526106339355141
Upgrade
Last Close Price
0.5510.873.9811.8812.208.64
Upgrade
PS Ratio
1.0019.147.7528.46252.76-
Upgrade
PB Ratio
-1.4535.381.708.173.172.02
Upgrade
P/TBV Ratio
-35.381.768.883.272.98
Upgrade
EV/Sales Ratio
2.6516.964.1722.11206.52-
Upgrade
Debt / Equity Ratio
-1.436.580.900.810.020.04
Upgrade
Asset Turnover
0.240.140.130.110.01-
Upgrade
Inventory Turnover
21.7581.38----
Upgrade
Quick Ratio
1.333.799.873.1113.2011.42
Upgrade
Current Ratio
1.664.0710.093.2513.6311.72
Upgrade
Return on Equity (ROE)
--213.02%-23.38%-103.60%-59.99%-69.34%
Upgrade
Return on Assets (ROA)
-57.97%-38.18%-35.57%-42.17%-34.06%-39.08%
Upgrade
Return on Capital (ROIC)
-79.94%-47.37%-44.52%-51.11%-36.68%-42.63%
Upgrade
Earnings Yield
-462.87%-23.84%-10.03%-22.61%-15.54%-30.46%
Upgrade
FCF Yield
-381.96%-19.91%-58.06%-13.36%-14.03%-27.59%
Upgrade
Buyback Yield / Dilution
-12.08%-37.56%-6.47%-34.57%-100.10%-33.30%
Upgrade
Total Shareholder Return
-12.08%-37.56%-6.47%-34.57%-100.10%-33.30%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.